Annals of Medicine and Surgery · 2022 · 30 citations · 4 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyOcular PharmacologyOral Drug DeliveryAlopecia EvaluationHair RestorationOral TreatmentProduct Safety ProfileRheumatoid Arthritis PharmacotherapySafety Profile CharacterizationTablets
Olumniant (Barcitinib) has gained swift approval by the Food and Drug Administration (FDA) as a promising medication for the treatment of adults with severe Alopecia Areata. This drug has proven to be effective for various conditions including Covid-19 and Rheumatoid Arthritis as well as being found to be less costly and minimally invasive, with no need for post-operative management. However, its use has some considerable potential implications before its prescription can be made commonplace. Therefore, more trials need to be conducted to establish a more rigid safety profile.
4
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
Lynn Petukhova, Madeleine Duvic, Maria Hordinsky et al. · Nature · 2010 · 820 citations · Full text
Life Sciences, Dermatology, Genetics +14
Autoimmune diseases in adults with atopic dermatitis
Y.M.F. Andersen, Alexander Egeberg, Gunnar Gislason et al. · Journal of the American Academy of Dermatology · 2016 · 148 citations
Brett King, Justin Ko, Seth Forman et al. · Journal of the American Academy of Dermatology · 2021 · 114 citations · Full text
Medicine, Dermatology, Pharmacology +13
Alopecia areata: Part 1: pathogenesis, diagnosis, and prognosis.
Frank Spano, Jeff Donovan · PubMed · 2015 · 91 citations
Medicine, Dermatology, Pathology +17